Multiple Stakeholders Come to Bat for Large Rheumatoid Arthritis PGx Trial
November 17, 2010
Multiple Stakeholders Come to Bat for Large Rheumatoid Arthritis PGx Trial
The trial, called Biomarkers of Anti-TNF Treatment Efficacy in Rheumatoid Arthritis to Define Unresponse Populations, or BATTER-UP, will enroll around 1,000 patients being treated by one of several marketed anti-TNF RA drugs: Enbrel, Remicade, Humira, Simponi, or Cimzia.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Dx Developers' Sales Pitch to Pharma Could be Key Factor in Marketing Some Tests
February 15, 2012 / Pharmacogenomics Reporter - New York Clears Crescendo Bio to Offer RA Test
April 18, 2013 / GenomeWeb Daily News - Opko Inks Deal with BMS to ID Response Markers for Orencia; Again Retools Peptoid-Based Dx Platform
January 18, 2013 / ProteoMonitor - Crescendo Aims for 'Full Launch Velocity' for Vectra DA, Focus on Educating RA Patients in 2013
January 9, 2013 / Pharmacogenomics Reporter - Crescendo Bioscience Raises $28M in Series D Financing Round
January 3, 2013 / GenomeWeb Daily News